WO2026038193 - NATURAL KILLER (NK) CELLS CRYOPRESERVATION
National phase entry is expected:
Publication Number
WO/2026/038193
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058297
International Filing Date
15.08.2025
Title **
[English]
NATURAL KILLER (NK) CELLS CRYOPRESERVATION
[French]
CRYOCONSERVATION DE CELLULES TUEUSES NATURELLES (NK)
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
JONES, Peter Anthony
ANDREEV, Nadejda
Priority Data
63/683,525
15.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3763 | |
| EPO | Filing, Examination, Granting | 43852 | |
| Japan | Filing, Examination, Granting | 3636 | |
| South Korea | Filing, Examination, Granting | 5089 | |
| USA | Filing, Examination, Granting | 16940 |
Total:
73,280
Contact Us
Abstract[English]
The present invention provides, among other things, compositions and methods for protecting cell therapy products from cryoinjury, in particular immune cells (e.g., NK cell products), during cryopreservation. The cryoformulation compositions and methods of the present invention reduce cryoinjury during cryopreserving process, thereby increasing cell therapy product recovery, viability and function after cryopreservation.[French]
La présente invention concerne, entre autres, des compositions et des procédés pour protéger des produits de thérapie cellulaire contre une cryolésion, en particulier des cellules immunitaires (par exemple, des produits de cellules NK), pendant la cryoconservation. Les compositions de cryoformulation et les procédés de la présente invention réduisent la cryolésion pendant le processus de cryoconservation, ce qui permet d'augmenter la récupération, la viabilité et la fonction du produit de thérapie cellulaire après cryoconservation.